Form 4: Jazz Pharmaceuticals EVP Philip L. Johnson Reports Acquisition of Ordinary Shares and Restricted Stock Units

Philip L. Johnson, EVP & Chief Financial Officer of Jazz Pharmaceuticals, reports the acquisition of ordinary shares and restricted stock units.

Summary

• On February 27, 2025, Philip L. Johnson, the EVP & Chief Financial Officer of Jazz Pharmaceuticals plc, reported the acquisition of 15,407 ordinary shares and 7,704 restricted stock units.
• The 15,407 restricted stock units vest in equal annual installments over four years starting March 5, 2025.
• Each restricted stock unit represents a contingent right to receive one ordinary share upon vesting.
• Johnson also acquired 166 ordinary shares under a Section 423 Employee Stock Purchase Plan on November 29, 2024.
• An additional 7,704 restricted stock units will vest in full on June 30, 2026.
• Following these transactions, Johnson beneficially owns 51,209 ordinary shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive as it reflects an executive increasing their stake in the company, which is generally seen as a good sign.

Positives

• The acquisition of shares and restricted stock units by a key executive signals confidence in the company's future performance.

Future Outlook

The document outlines the vesting schedule for the restricted stock units, indicating future dates when Johnson will receive ordinary shares.

Industry Context

This filing is a routine disclosure related to executive compensation and stock ownership, common in the pharmaceutical industry.

Stakeholder Impact

• The increased stake of a key executive could positively influence shareholder confidence.

Key Dates